Pharmac funds and widens access to melanoma medicines
Pharmac is funding more medicines for people with skin cancer (melanoma), from 1 June 2025. The decision includes widening access to pembrolizumab (branded as Keytruda) and funding dabrafenib (branded as Tafinlar) and trametinib (branded as Mekinist) for …